| Name | Title | Contact Details |
|---|
Must be 21+ We aim higher for the wellness of our customers, through the power of cannabis.
Triangle Chapter of the American Red Cross is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
One of the fastest growing companies in America, Shields Health Solutions partners with hospital leaders on every aspect of specialty pharmacy creation and growth. The company provides the fastest, lowest risk model for Hospital leaders to create and grow a hospital-owned specialty pharmacy business, whether starting from scratch or adding specialty capabilities to a hospital`s existing pharmacy programs.
Key Benefit Administrators is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Indianapolis, IN. To find more information about Key Benefit Administrators, please visit www.keybenefit.com
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.